The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 05, 2015

Filed:

Feb. 12, 2014
Applicants:

Oxigene, Inc., South San Francisco, CA (US);

Baylor University, Waco, TX (US);

Inventors:

David J. Chaplin, Watlington, GB;

Charles Manly Garner, III, McGregor, TX (US);

Robert Ronald Kane, Waco, TX (US);

Kevin G. Pinney, Woodway, TX (US);

Joseph Anthony Prezioso, Boston, MA (US);

Klaus Edvardsen, Klampenborg, DK;

Assignees:

OXiGENE, Inc., South San Francisco, CA (US);

Baylor University, Waco, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 207/00 (2005.12); C07C 207/04 (2005.12); C07C 205/37 (2005.12); C07C 205/00 (2005.12); C07C 217/00 (2005.12); C07C 237/00 (2005.12); C07C 217/84 (2005.12); C07C 237/04 (2005.12); C07C 43/00 (2005.12); C07C 45/63 (2005.12); C07C 43/23 (2005.12); C07F 9/00 (2005.12); C07C 9/12 (2005.12); C07C 47/575 (2005.12); C07F 9/12 (2005.12);
U.S. Cl.
CPC ...
C07C 43/23 (2012.12); C07C 9/12 (2012.12); C07C 45/63 (2012.12); C07C 47/575 (2012.12); C07C 205/37 (2012.12); C07C 207/04 (2012.12); C07C 217/84 (2012.12); C07C 237/04 (2012.12);
Abstract

Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.


Find Patent Forward Citations

Loading…